Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.

Raab M, Sanhaji M, Pietsch L, Béquignon I, Herbrand AK, Süß E, Gande SL, Caspar B, Kudlinzki D, Saxena K, Sreeramulu S, Schwalbe H, Strebhardt K, Biondi RM.

ACS Chem Biol. 2018 Jun 28. doi: 10.1021/acschembio.7b01078. [Epub ahead of print]

PMID:
29927572
2.

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.

Noack S, Raab M, Matthess Y, Sanhaji M, Krämer A, Győrffy B, Kaderali L, El-Balat A, Becker S, Strebhardt K.

Oncotarget. 2018 May 25;9(40):25842-25859. doi: 10.18632/oncotarget.25386. eCollection 2018 May 25.

3.

PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.

Raab M, Sanhaji M, Matthess Y, Hörlin A, Lorenz I, Dötsch C, Habbe N, Waidmann O, Kurunci-Csacsko E, Firestein R, Becker S, Strebhardt K.

Nat Commun. 2018 Mar 16;9(1):1106. doi: 10.1038/s41467-018-03494-4.

4.

Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.

Zhang P, Kawakami H, Liu W, Zeng X, Strebhardt K, Tao K, Huang S, Sinicrope FA.

Mol Cancer Res. 2018 Mar;16(3):378-389. doi: 10.1158/1541-7786.MCR-17-0404. Epub 2017 Dec 12.

PMID:
29233910
5.

Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus.

Plissonnier ML, Lahlali T, Raab M, Michelet M, Romero-López C, Rivoire M, Strebhardt K, Durantel D, Levrero M, Mehlen P, Zoulim F, Parent R.

Oncogene. 2017 Nov 30;36(48):6712-6724. doi: 10.1038/onc.2017.271. Epub 2017 Aug 7.

PMID:
28783179
6.

LFA-1 activates focal adhesion kinases FAK1/PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate formation.

Raab M, Lu Y, Kohler K, Smith X, Strebhardt K, Rudd CE.

Nat Commun. 2017 Jul 12;8:16001. doi: 10.1038/ncomms16001.

7.

Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy.

Balermpas P, Martin D, Wieland U, Rave-Fränk M, Strebhardt K, Rödel C, Fokas E, Rödel F.

Oncoimmunology. 2017 Feb 6;6(3):e1288331. doi: 10.1080/2162402X.2017.1288331. eCollection 2017.

8.

Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.

Rödel F, Martin D, Helmke C, Balermpas P, Fokas E, Wieland U, Rave-Fränk M, Kitz J, Matthess Y, Raab M, Strebhardt K, Rödel C.

Oncotarget. 2016 Aug 16;7(33):53339-53349. doi: 10.18632/oncotarget.10801.

9.

Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8.

Helmke C, Raab M, Rödel F, Matthess Y, Oellerich T, Mandal R, Sanhaji M, Urlaub H, Rödel C, Becker S, Strebhardt K.

Cell Res. 2016 Aug;26(8):914-34. doi: 10.1038/cr.2016.78. Epub 2016 Jun 21.

10.

Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Li J, Karki A, Hodges KB, Ahmad N, Zoubeidi A, Strebhardt K, Ratliff TL, Konieczny SF, Liu X.

Mol Cell Biol. 2015 Dec;35(24):4185-98. doi: 10.1128/MCB.00825-15. Epub 2015 Oct 5.

11.

Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Mandal R, Becker S, Strebhardt K.

Oncogene. 2016 May 19;35(20):2547-61. doi: 10.1038/onc.2015.329. Epub 2015 Sep 14. Review.

PMID:
26364606
12.

Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Li Z, Lu Y, Ahmad N, Strebhardt K, Liu X.

Cell Cycle. 2015;14(19):3030-9. doi: 10.1080/15384101.2015.1080397.

13.

Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.

Scharow A, Raab M, Saxena K, Sreeramulu S, Kudlinzki D, Gande S, Dötsch C, Kurunci-Csacsko E, Klaeger S, Kuster B, Schwalbe H, Strebhardt K, Berg T.

ACS Chem Biol. 2015 Nov 20;10(11):2570-9. doi: 10.1021/acschembio.5b00565. Epub 2015 Aug 27.

PMID:
26279064
14.

Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.

Strebhardt K.

Cell Cycle. 2015;14(14):2193-4. doi: 10.1080/15384101.2015.1056611. Epub 2015 Jun 1. No abstract available.

15.

Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.

De Giorgi U, Yuan J, Moroni M, Veronese S, Sartore-Bianchi A, Broggini M, Rosti G, Strebhardt K, Ruffini PA.

Int J Biol Markers. 2015 Jul 22;30(3):e275-81. doi: 10.5301/jbm.5000149.

PMID:
25982682
16.

The role of Plk3 in oncogenesis.

Helmke C, Becker S, Strebhardt K.

Oncogene. 2016 Jan 14;35(2):135-47. doi: 10.1038/onc.2015.105. Epub 2015 Apr 27. Review.

PMID:
25915845
17.

Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.

Strebhardt K, Becker S, Matthess Y.

Expert Opin Drug Discov. 2015 Jan;10(1):1-8. doi: 10.1517/17460441.2015.962510. Epub 2014 Sep 29.

PMID:
25263688
18.

Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.

Raab M, Krämer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dötsch C, Bug G, Ottmann O, Becker S, Pachl F, Kuster B, Strebhardt K.

Mol Oncol. 2015 Jan;9(1):140-54. doi: 10.1016/j.molonc.2014.07.020. Epub 2014 Aug 11.

19.

Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells.

Raab M, Pachl F, Krämer A, Kurunci-Csacsko E, Dötsch C, Knecht R, Becker S, Kuster B, Strebhardt K.

Cell Res. 2014 Sep;24(9):1141-5. doi: 10.1038/cr.2014.86. Epub 2014 Jul 1. No abstract available.

20.

Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosis.

Matthess Y, Raab M, Knecht R, Becker S, Strebhardt K.

Mol Oncol. 2014 May;8(3):596-608. doi: 10.1016/j.molonc.2013.12.013. Epub 2014 Jan 17.

21.

pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.

Mandal R, Raab M, Matthess Y, Becker S, Knecht R, Strebhardt K.

Mol Oncol. 2014 Mar;8(2):232-49. doi: 10.1016/j.molonc.2013.11.003. Epub 2013 Nov 20.

22.

Plk1: unexpected roles in DNA replication.

Mandal R, Strebhardt K.

Cell Res. 2013 Nov;23(11):1251-3. doi: 10.1038/cr.2013.130. Epub 2013 Sep 17.

23.

Polo-like kinases in AML.

Berg T, Bug G, Ottmann OG, Strebhardt K.

Expert Opin Investig Drugs. 2012 Aug;21(8):1069-74. doi: 10.1517/13543784.2012.691163. Epub 2012 Jun 6.

PMID:
22667760
24.

A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.

Reindl W, Strebhardt K, Berg T.

Methods Mol Biol. 2012;795:69-81. doi: 10.1007/978-1-61779-337-0_5.

PMID:
21960216
25.

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Yuan J, Sanhaji M, Krämer A, Reindl W, Hofmann M, Kreis NN, Zimmer B, Berg T, Strebhardt K.

Am J Pathol. 2011 Oct;179(4):2091-9. doi: 10.1016/j.ajpath.2011.06.031. Epub 2011 Aug 10.

26.

Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.

Raab M, Kappel S, Krämer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, Busch DH, Esposito I, Fuchs H, Gailus-Durner V, Klingenspor M, Wolf E, Sänger N, Prinz F, Angelis MH, Seibler J, Yuan J, Bergmann M, Knecht R, Kreft B, Strebhardt K.

Nat Commun. 2011 Jul 19;2:395. doi: 10.1038/ncomms1395.

27.

SKAP1 protein PH domain determines RapL membrane localization and Rap1 protein complex formation for T cell receptor (TCR) activation of LFA-1.

Raab M, Smith X, Matthess Y, Strebhardt K, Rudd CE.

J Biol Chem. 2011 Aug 26;286(34):29663-70. doi: 10.1074/jbc.M111.222661. Epub 2011 Jun 13.

28.

Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ.

Sänger N, Effenberger KE, Riethdorf S, Van Haasteren V, Gauwerky J, Wiegratz I, Strebhardt K, Kaufmann M, Pantel K.

Int J Cancer. 2011 Nov 15;129(10):2522-6. doi: 10.1002/ijc.25895. Epub 2011 Mar 25.

29.

Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity.

Matthess Y, Raab M, Sanhaji M, Lavrik IN, Strebhardt K.

Mol Cell Biol. 2010 Dec;30(24):5726-40. doi: 10.1128/MCB.00731-10. Epub 2010 Oct 11.

30.

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Strebhardt K.

Nat Rev Drug Discov. 2010 Aug;9(8):643-60. doi: 10.1038/nrd3184. Review.

PMID:
20671765
31.

Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells.

Kreis NN, Sanhaji M, Krämer A, Sommer K, Rödel F, Strebhardt K, Yuan J.

Oncogene. 2010 Oct 14;29(41):5591-603. doi: 10.1038/onc.2010.290. Epub 2010 Jul 26.

PMID:
20661218
32.

Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

Rödel F, Keppner S, Capalbo G, Bashary R, Kaufmann M, Rödel C, Strebhardt K, Spänkuch B.

Am J Pathol. 2010 Aug;177(2):918-29. doi: 10.2353/ajpath.2010.100040. Epub 2010 Jun 25.

33.

Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1.

Sanhaji M, Friel CT, Kreis NN, Krämer A, Martin C, Howard J, Strebhardt K, Yuan J.

Mol Cell Biol. 2010 Jun;30(11):2594-607. doi: 10.1128/MCB.00098-10. Epub 2010 Apr 5.

34.

T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes.

Raab M, Wang H, Lu Y, Smith X, Wu Z, Strebhardt K, Ladbury JE, Rudd CE.

Immunity. 2010 Apr 23;32(4):541-56. doi: 10.1016/j.immuni.2010.03.007. Epub 2010 Mar 25.

35.

Biological impact of freezing Plk1 in its inactive conformation in cancer cells.

Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B.

Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16.

PMID:
20139717
36.

Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.

Reindl W, Gräber M, Strebhardt K, Berg T.

Anal Biochem. 2009 Dec 15;395(2):189-94. doi: 10.1016/j.ab.2009.08.031. Epub 2009 Aug 27.

PMID:
19716361
37.

Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.

Steinhauser I, Langer K, Strebhardt K, Spänkuch B.

J Drug Target. 2009 Sep;17(8):627-37. doi: 10.1080/10611860903118823.

PMID:
19591537
38.

A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chembiochem. 2009 May 4;10(7):1145-8. doi: 10.1002/cbic.200900059.

PMID:
19350612
39.

Direct quantification of polo-like kinase 1 activity in cells and tissues using a highly sensitive and specific ELISA assay.

Park JE, Li L, Park J, Knecht R, Strebhardt K, Yuspa SH, Lee KS.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1725-30. doi: 10.1073/pnas.0812135106. Epub 2009 Jan 30.

40.

Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1).

Kreis NN, Sommer K, Sanhaji M, Krämer A, Matthess Y, Kaufmann M, Strebhardt K, Yuan J.

Cell Cycle. 2009 Feb 1;8(3):460-72. Epub 2009 Feb 18.

PMID:
19177004
41.

Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.

Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K, Yuan J.

BMC Cancer. 2008 Dec 29;8:391. doi: 10.1186/1471-2407-8-391.

42.

A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.

Reindl W, Strebhardt K, Berg T.

Anal Biochem. 2008 Dec 15;383(2):205-9. doi: 10.1016/j.ab.2008.08.014. Epub 2008 Aug 22.

PMID:
18793607
43.

Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.

Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B.

Biomaterials. 2008 Oct;29(29):4022-8. doi: 10.1016/j.biomaterials.2008.07.001. Epub 2008 Jul 23.

PMID:
18653231
44.

Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.

Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Strebhardt K, Knecht R.

Clin Otolaryngol. 2008 Jun;33(3):245-51. doi: 10.1111/j.1749-4486.2008.01702.x.

PMID:
18559031
45.

Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T.

Chem Biol. 2008 May;15(5):459-66. doi: 10.1016/j.chembiol.2008.03.013.

46.

Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.

Spänkuch B, Strebhardt K.

Curr Pharm Des. 2008;14(11):1098-112. Review.

PMID:
18473857
47.

Paul Ehrlich's magic bullet concept: 100 years of progress.

Strebhardt K, Ullrich A.

Nat Rev Cancer. 2008 Jun;8(6):473-80. doi: 10.1038/nrc2394. Epub 2008 May 12. Review.

PMID:
18469827
48.

Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.

Spänkuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K.

Neoplasia. 2008 Mar;10(3):223-34.

49.

Adaptor SKAP-55 binds p21 activating exchange factor RasGRP1 and negatively regulates the p21-ERK pathway in T-cells.

Schneider H, Wang H, Raab M, Valk E, Smith X, Lovatt M, Wu Z, Maqueira-Iglesias B, Strebhardt K, Rudd CE.

PLoS One. 2008 Mar 5;3(3):e1718. doi: 10.1371/journal.pone.0001718.

50.

Silencing of mammalian genes by tetracycline-inducible shRNA expression.

Kappel S, Matthess Y, Kaufmann M, Strebhardt K.

Nat Protoc. 2007;2(12):3257-69.

PMID:
18079726

Supplemental Content

Loading ...
Support Center